Activatable photothermal agents with target-initiated large spectral separation for highly effective reduction of side effects.

ABSTRACT: Photothermal agents (PTAs) with minimized side effects are critical for transforming cancer photothermal therapy (PTT) into clinical applications. However, most currently available PTAs lack true selective activation to reduce side effects because of heavy spectral overlap between photothermal agents and their corresponding products. This study reports the construction of activatable PTAs with target-initiated large spectral separation for highly effective reduction of side effects. Such designed probes involve two H₂O₂-activatable PTAs, aza-BOD-B1 (single activatable site) and aza-BOD-B2 (multiple activatable site). After interacting with H₂O₂, aza-BOD-B1 only displays a mild absorption redshift (60 nm) from 750 nm to 810 nm with serious spectra

SUBMITTER: Sun J 

PROVIDER: S-EPMC9400798 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature